311 results
Page 7 of 16
8-K
EX-99.1
mfi1g5t6
19 Oct 12
A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer
12:00am
8-K
EX-99.1
qs0cb91m
17 Oct 12
A.P. Pharma Announces PDUFA Action Date
12:00am
8-K
EX-99.1
cfol5i xyh5x
1 Oct 12
A.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting
12:00am
8-K
EX-99.1
rz2og7ojmu
10 Sep 12
A.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President of Business Development
12:00am
424B3
0bqe7nnig4v39c1u
9 Aug 12
Prospectus supplement
12:00am
424B3
7h8sb9z
9 Aug 12
Prospectus supplement
12:00am
8-K
EX-99.1
m6fm qelhx7bqt65ezhe
2 Aug 12
A.P. Pharma Announces Second Quarter 2012 Financial Results and Highlights Recent Corporate Progress
12:00am
8-K
EX-99.1
igsu saspsf
31 Jul 12
A.P. Pharma Appoints Robert Rosen to Its Board of Directors
12:00am
8-K
EX-99.1
03ignczl
25 Jul 12
A.P. Pharma to Raise $53.6 Million in Common Stock Offering
12:00am
8-K
EX-10.1
lk4zt
25 Jul 12
A.P. Pharma to Raise $53.6 Million in Common Stock Offering
12:00am
8-K
EX-99.2
r6oem
25 Jul 12
A.P. Pharma to Raise $53.6 Million in Common Stock Offering
12:00am
8-K
EX-99.1
e7vpu1r8 w4dme4xy
12 Jul 12
A.P. Pharma Announces the Allowance of
12:00am
8-K
EX-99.1
y81ihd
3 Jul 12
A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting
12:00am
8-K
EX-99.1
3tn 3dofk8wnjhk0hr5k
22 Jun 12
A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study
12:00am
8-K
6ttw mcfz
22 Jun 12
A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study
12:00am
424B3
8e0uxt
3 Apr 12
Prospectus supplement
12:00am
424B3
v42uvw
3 Apr 12
Prospectus supplement
12:00am